Screening, Prevention, Etiology, and Cancer Survivorship Program Summary The goal of the SPECS Program is to address the broad spectrum of cancer control, including etiology, prevention, early detection, treatment, and survivorship.
The specific aims of the SPECS Program are to 1) prevent cancer by identifying risk factors and developing novel products and public policies to reduce exposure, 2) detect cancer at an early stage and understand the risks and benefits of diagnosis and treatment options, and 3) identify factors that impact prognosis and quality of life among cancer survivors. The SPECS Program is led by Anne Joseph, MD, MPH; Heather Nelson, MPH, PhD; and Karen Kuntz, ScD and has 49 members, representing 18 departments, 8 schools or colleges, and 4 external organizations. For the last budget year, these members were supported by $2.3 million in direct research funding from the National Cancer Institute; support from all sponsored sources totaled $8.0 million in direct research funding. Since 2013, Program members have published 1564 papers (6% in high-impact journals), 20% of which resulted from intraprogrammatic collaborations, 12% from interprogrammatic collaborations, and 85% from external collaborations. Since 2013, 185 clinical trials in all clinical research categories have opened under this programmatic area and have accrued 13,122 subjects. The Masonic Cancer Center has provided substantial value to the program, including access to shared resources, investment in the recruitment of a new faculty member, funding of 21 pilot projects totaling over $500,000, and 5 research retreats. The SPECS Program research portfolio spans the cancer continuum, including the study of etiology, prevention, early detection, diagnosis, treatment, and survivorship. Crosscutting themes include communication, health disparities, health promotion, biomarkers, epidemiology, decision modeling and cost-effectiveness analysis, and public policy. SPECS research is directed at the cancer burdens of the diverse populations of Minnesota, including the needs of new immigrant, Native American, and other vulnerable populations. SPECS researcher has particular focus on cervical, colon, lung, and prostate cancers, mirroring the disease incidences of our populations. SPECS investigators make excellent use of Masonic Cancer Center Shared Resources, especially Analytical Biochemistry, Biostatistics, and Clinical Informatics. There is an active training component, including T32s on cancer and health disparities, pediatric cancer epidemiology, and health services research. SPECS directly addresses several Scientific Priorities for Growth (SPG) including, SPG4 ? use biomarkers to individualize cancer prevention, SPG5 ? Establish a new Minnesota-based cohort, and SPG6 ? Develop effective methods to increase adoption of evidence-based cancer prevention behaviors by vulnerable populations with disproportionate cancer burden in Minnesota.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA077598-23
Application #
10086451
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1998-06-01
Project End
2024-01-31
Budget Start
2021-02-01
Budget End
2022-01-31
Support Year
23
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Lin, Lifeng; Chu, Haitao; Murad, Mohammad Hassan et al. (2018) Empirical Comparison of Publication Bias Tests in Meta-Analysis. J Gen Intern Med 33:1260-1267
Rashidi, Armin; Ebadi, Maryam; Said, Bassil et al. (2018) Absence of early HHV-6 reactivation after cord blood allograft predicts powerful graft-versus-tumor effect. Am J Hematol :
Bejanyan, Nelli; Brunstein, Claudio G; Cao, Qing et al. (2018) Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD. Blood Adv 2:909-922
Bachanova, Veronika; Sarhan, Dhifaf; DeFor, Todd E et al. (2018) Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells. Cancer Immunol Immunother 67:483-494
Hupp, Meghan; Williams, Sarah; Dunnette, Brian et al. (2018) Comparison of evaluation techniques, including digital image analysis, for MYC protein expression by immunohistochemical stain in aggressive B-cell lymphomas. Hum Pathol :
Rashidi, Armin; Shanley, Ryan; Holtan, Shernan G et al. (2018) Pretransplant Serum Citrulline Predicts Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:2190-2196
Ma, Bin; Zarth, Adam T; Carlson, Erik S et al. (2018) Methyl DNA Phosphate Adduct Formation in Rats Treated Chronically with 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone and Enantiomers of Its Metabolite 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol. Chem Res Toxicol 31:48-57
Hatsukami, Dorothy K; Luo, Xianghua; Jensen, Joni A et al. (2018) Effect of Immediate vs Gradual Reduction in Nicotine Content of Cigarettes on Biomarkers of Smoke Exposure: A Randomized Clinical Trial. JAMA 320:880-891
Lee, Hak Rae; Leslie, Faith; Azarin, Samira M (2018) A facile in vitro platform to study cancer cell dormancy under hypoxic microenvironments using CoCl2. J Biol Eng 12:12
Yang, Libang; Herrera, Jeremy; Gilbertsen, Adam et al. (2018) IL-8 mediates idiopathic pulmonary fibrosis mesenchymal progenitor cell fibrogenicity. Am J Physiol Lung Cell Mol Physiol 314:L127-L136

Showing the most recent 10 out of 1013 publications